

Press release

22 February 2018



Evonetix shortlisted for Business Weekly awards

CAMBRIDGE, UK, 22nd February 2018 – EVONETIX LTD ('Evonetix'), the Cambridge-based company pioneering an innovative approach to enable scalable and high-fidelity gene synthesis, announced today that it has been short-listed for the 2018 Business Weekly awards.

The company has been short-listed for Startup of the Year, Disruptive Technology, Life Science Innovation and Business of the Year. The final winners will be announced at the Business Weekly presentation dinner at Queens' College, Cambridge on Wednesday, 21 March 2018.


Tim Brears, Evonetix CEO, said: 'It is a great honour to be shortlisted for these hugely prestigious awards by Business Weekly. We look forward to the next stage of the process with great anticipation'.

Evonetix was founded in 2016 to develop technology that enables the parallel synthesis of DNA on silicon arrays, to facilitate the fast-emerging field of synthetic biology, where there is increasing demand for high-throughput and highly accurate DNA synthesis. The company's platform uses an addressable silicon array to direct the synthesis of DNA at many sites in parallel, followed by an error-detection process to allow the assembly of high-fidelity DNA at scale.

ENDS



Tim Brears, CEO, Evonetix



Prototype silicon arrays

For further information, please contact:

Tim Brears

Evonetix Ltd

Tel: 01223 930307

E-mail: tim.brears@evonetix.com

Lorna Cuddon

Zyme Communications

Tel: 07811 996942

E-mail: lorna.cuddon@zymecommunications.com

Notes to Editors

About Evonetix Ltd:

Evonetix is developing a novel, highly disruptive approach to gene synthesis, the technology which underpins the rapidly growing field of synthetic biology.

The company was co-founded in 2016 by breakthrough innovation specialists Cambridge Consultants Ltd and Providence Investment Company Limited with key staff from next-generation sequencing company Solexa. Its executive management team has many years' experience in the development and delivery of successful biotech ventures.

There are two key components of the Evonetix approach: (i) a highly scalable platform, with up to 10,000 sites for DNA synthesis, at each of which there is independent, exquisite control of the synthesis process; and (ii) the ability to assemble DNA molecules with a very low error rate using a process of error detection throughout assembly. In addition, the approach will permit the synthesis of 'difficult' sequences, such as those with a high GC content or with repeats.

The company's technology is based upon a novel silicon array, manufactured with semiconductor microfabrication techniques and permitting the independent control required at the miniaturised reaction sites. This will allow massive parallelism in the DNA synthesis process and therefore very high throughput. The approach will be suitable for the large-scale projects of synthetic biology.

For further information see www.evonetix.com.

About synthetic biology:

With the huge increase in DNA sequence information available to mankind over the past ten years, there now exists an unprecedented opportunity to engineer metabolic pathways and organisms, improve industrial processes, create new processes, engineer genomes with new and improved traits and use DNA as a medium for data storage. This opportunity, known as synthetic biology, will grow rapidly over the coming years, reaching \$40 billion in value in the early 2020s. Synthetic biology will have a massive impact across many industries and will be fundamental to helping us manage the Earth's resources.

However, only a highly disruptive technology is likely to achieve the significant improvements in DNA synthesis required to enable and facilitate these opportunities. Evonetix believes that, by providing high-fidelity DNA at scale, without the need for post-synthesis error correction, it will be well placed to capture a significant part of the growing multibillion-dollar synthetic biology opportunity.